Pancreatic Ductal Adenocarcinoma
Conditions
Keywords
BRCA Mutation Carriers, PDAC carriers, BRCAmut carriers, Registry, 13-217
Brief summary
The purpose of this study is to better understand why pancreatic cancer develops in some people who are known carriers of the gene mutation (an abnormality) called BRCA, or its close relative PALB2. The investigators hope to do this by establishing a BRCA/PALB2 mutation carriers Pancreatic Ductal Adenocarcinoma (the common form of pancreatic cancer) Registry. A registry is a database of information.
Interventions
BEHAVIORALThe risk assessment questionnaire
OTHERBlood specimens
OTHERtumor tissue samples will be requested
Sponsors
Abramson Cancer Center at Penn Medicine
Shaare Zedek Medical Center
Sheba Medical Center
Dana-Farber Cancer Institute
Johns Hopkins University
Memorial Sloan Kettering Cancer Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* BRCA mutation carrier is defined as a person with any mutation of the BRCA gene, including BRCA1, or BRCA2. PALB2mut patients are also eligible. * Relative of a BRCA PDAC patient is defined as a first-degree relative, which includes, parents, siblings or children. BRCAmut PDAC Group: Study Group A: Ashkenazi Jewish descent * Known BRCA mutation carrier. * Ashkenazi Jewish Descent (at least one parent of Ashkenazi Jewish origin). * Histologic proof of primary pancreatic ductal adenocarcinoma. * May have either potentially curable (resectable) primary PDAC, localized but unresectable primary PDAC, or metastatic (stage IV) PDAC. * Prior personal history of other malignancy; either prior or currently active, including breast , ovarian or prostate cancer is allowed. * Both previously treated and previously untreated patients are eligible. Previous treatment may include surgical resection, regional radiation therapy, or systemic therapy. Patient may be receiving active therapy. * Willing to provide blood specimens for correlative studies. * Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material). New tumor biopsies are not required for entrance into the Registry. BRCAmut PDAC Group: Study Group B: non-Ashkenazi Jewish descent * Know n BRCA mutation carrier. * Histologic proof of primary pancreatic ductal adenocarcinoma. * May have either potentially curable (resectable) primary PDAC, localized but unresectable primary PDAC, or metastatic (stage IV) PDAC. * Prior personal history of other malignancy; either prior or currently active, including breast, ovarian, or prostate cancer is allowed. * Both previously treated and previously untreated patients are eligible. Previous treatment may include surgical resection, regional radiation therapy, or systemic therapy. Patient may be receiving active therapy. * Willing to provide blood specimens for correlative studies. * Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material). New tumor biopsies are not required for entrance into the Registry. BRCA mutation carrier, relative of a BRCA PDAC patients, without PDAC or other BRCAmut related malignancy: (Control Cohort 1A): Ashkenazi Jewish descent * Known BRCA mutation carrier. * Ashkenazi Jewish Descent (at least one parent of Ashkenazi Jewish origin). * No current or prior history of PDAC. * Relative of a BRCAmut PDAC patient; no prior or active personal history of breast, ovarian, or prostate cancer * Willing to provide blood specimens for correlative studies. BRCA mutation carrier, relative of a BRCA PDAC patients, without PDAC or other BRCAmut related malignancy: (Control Cohort 1B): non-Ashkenazi Jewish descent * Know n BRCA mutation carrier. * No current or prior history of PDAC. * First or second degree relative of a BRCAmut PDAC patient; no prior or active personal history of breast, ovarian, or prostate cancer. * Willing to provide blood specimens for correlative studies. BRCAmut Carrier relative of a BRCAmut PDAC patient who themselves have prior or active BRCAmut related malignancy (Control Cohort 2A):Ashkenazi Jewish descent * Known BRCA mutation carrier. * Ashkenazi Jewish Descent (at least one parent of Ashkenazi Jewish origin). * No current or prior history of PDAC. * Relative of a BRCAmut PDAC patient. * Prior or active personal history of any BRCA-related cancer. * Willing to provide blood specimens for correlative studies. BRCAmut Carrier relative of a BRCAmut PDAC patient who themselves have prior or active BRCAmut related malignancy (Control Cohort 2B): non-Ashkenazi Jewish descent * Know n BRCA mutation carrier. * No current or prior history of PDAC. * First or second degree relative of a BRCAmut PDAC patient. * Prior or active personal history of any BRCA-related cancer. * Willing to provide blood specimens for correlative studies. BRCAmut carrier who is not related to a BRCAmut PDAC patient: (Control cohort 3A) Ashkenazi Jewish descent * Known BRCAmut carrier. * Ashkenazi Jewish decent (at least one parent of Ashkenazi Jewish origin). * No current or prior personal history of PDAC. * Prior personal history of other malignancy including breast, ovarian or prostate cancer is allowed. * Willing to provide blood specimens for correlative studies. BRCAmut carrier who is not related to a BRCAmut PDAC patient: (Control cohort 3B) non-Ashkenazi Jewish descent * Know n BRCAmut carrier. * No current or prior personal history of PDAC. * Prior personal history of other malignancy including breast, ovarian, or prostate cancer is allowed. * Willing to provide blood specimens for correlative studies. Non-BRCAmut carriers with histologically proven PDAC: (Control cohort 4) Tested for and negative for the BRCA founder mutations. * Ashkenazi Jewish Descent (at least one parent of Ashkenazi Jewish origin). * Not related to known BRCAmut carrier. * Histologic proof of primary pancreatic ductal adenocarcinoma. May have either potentially curable (resectable) primary PDAC, localized but unresectable primary PDAC, or metastatic (stage IV) PDAC. * Both previously treated and previously untreated patients are eligible. Previous treatment may include surgical resection, regional radiation therapy, or systemic therapy. Patient may be receiving active therapy. * Willing to provide blood specimens for correlative studies. * Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material). New tumor biopsies are not required for entrance into the Registry
Exclusion criteria
* Individuals will be excluded from the Registry if they: * Are unable to sign informed consent for medical or other reasons. Do not speak English (MSK and UPenn) or do not speak English or Hebrew (BCGC Sites). * Are under 21 years of age. * Not willing to provide blood samples for correlative studies.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| prospective Registry | 3 years | Establishment of a BRCA mutation carriers PDAC Registry with appropriate control groups, and collection and storage of biological material for future studies. |
Countries
Israel, United States
Outcome results
None listed